107 related articles for article (PubMed ID: 25316312)
1. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.
McDonnell AM; Lesterhuis WJ; Khong A; Nowak AK; Lake RA; Currie AJ; Robinson BW
Eur J Immunol; 2015 Jan; 45(1):49-59. PubMed ID: 25316312
[TBL] [Abstract][Full Text] [Related]
2. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
3. Type I interferon activates MHC class I-dressed CD11b
Duong E; Fessenden TB; Lutz E; Dinter T; Yim L; Blatt S; Bhutkar A; Wittrup KD; Spranger S
Immunity; 2022 Feb; 55(2):308-323.e9. PubMed ID: 34800368
[TBL] [Abstract][Full Text] [Related]
4. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo.
Jackaman C; Majewski D; Fox SA; Nowak AK; Nelson DJ
Cancer Immunol Immunother; 2012 Dec; 61(12):2343-56. PubMed ID: 22714286
[TBL] [Abstract][Full Text] [Related]
6. Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy.
Moussion C; Delamarre L
Semin Immunol; 2024 Feb; 71():101848. PubMed ID: 38035643
[TBL] [Abstract][Full Text] [Related]
7. Antigen cross-presentation in dendric cells: From bench to bedside.
Zhang T; Aipire A; Li Y; Guo C; Li J
Biomed Pharmacother; 2023 Dec; 168():115758. PubMed ID: 37866002
[TBL] [Abstract][Full Text] [Related]
8. Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer.
Lu Z; Chen J; Yu P; Atherton MJ; Gui J; Tomar VS; Middleton JD; Sullivan NT; Singhal S; George SS; Woolfork AG; Weljie AM; Hai T; Eruslanov EB; Fuchs SY
Nat Commun; 2022 Nov; 13(1):6623. PubMed ID: 36333297
[TBL] [Abstract][Full Text] [Related]
9. Exploring dendritic cell subtypes in cancer immunotherapy: unraveling the role of mature regulatory dendritic cells.
Badillo O; Helfridsson L; Niemi J; Hellström M
Ups J Med Sci; 2024; 129():. PubMed ID: 38716077
[TBL] [Abstract][Full Text] [Related]
10. The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity.
Böttcher JP; Reis e Sousa C
Trends Cancer; 2018 Nov; 4(11):784-792. PubMed ID: 30352680
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment and lymphocyte infiltration.
Rahir G; Moser M
Cancer Immunol Immunother; 2012 Jun; 61(6):751-9. PubMed ID: 22488275
[TBL] [Abstract][Full Text] [Related]
12. Nanoenabled Disruption of Multiple Barriers in Antigen Cross-Presentation of Dendritic Cells
An J; Zhang K; Wang B; Wu S; Wang Y; Zhang H; Zhang Z; Liu J; Shi J
ACS Nano; 2020 Jun; 14(6):7639-7650. PubMed ID: 32427462
[TBL] [Abstract][Full Text] [Related]
13. Once upon a prime: DCs shape cancer immunity.
Zagorulya M; Spranger S
Trends Cancer; 2023 Feb; 9(2):172-184. PubMed ID: 36357313
[TBL] [Abstract][Full Text] [Related]
14. Emerging roles for tumor stroma in antigen presentation and anti-cancer immunity.
Papadas A; Huang Y; Cicala A; Dou Y; Fields M; Gibbons A; Hong D; Lagal DJ; Quintana V; Rizo A; Zomalan B; Asimakopoulos F
Biochem Soc Trans; 2023 Dec; 51(6):2017-2028. PubMed ID: 38031753
[TBL] [Abstract][Full Text] [Related]
15. Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression.
Nguyen KB; Roerden M; Copeland CJ; Backlund CM; Klop-Packel NG; Remba T; Kim B; Singh NK; Birnbaum ME; Irvine DJ; Spranger S
Elife; 2023 Aug; 12():. PubMed ID: 37548358
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating dendritic cell states are conserved across solid human cancers.
Gerhard GM; Bill R; Messemaker M; Klein AM; Pittet MJ
J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33601412
[TBL] [Abstract][Full Text] [Related]
17. Exploiting Autophagy-Dependent Neoantigen Presentation in Tumor Microenvironment.
Koustas E; Trifylli EM; Sarantis P; Papadopoulos N; Papanikolopoulos K; Aloizos G; Damaskos C; Garmpis N; Garmpi A; Matthaios D; Karamouzis MV
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833401
[TBL] [Abstract][Full Text] [Related]
18. The Origin and Immune Recognition of Tumor-Specific Antigens.
Apavaloaei A; Hardy MP; Thibault P; Perreault C
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32932620
[TBL] [Abstract][Full Text] [Related]
19. DCs at the center of help: Origins and evolution of the three-cell-type hypothesis.
Wu R; Murphy KM
J Exp Med; 2022 Jul; 219(7):. PubMed ID: 35543702
[TBL] [Abstract][Full Text] [Related]
20. Correction to "Nanoenabled Disruption of Multiple Barriers in Antigen Cross-Presentation of Dendritic Cells via Calcium Interference for Enhanced Chemo-Immunotherapy".
An J; Zhang K; Wang B; Wu S; Wang Y; Zhang H; Zhang Z; Liu J; Shi J
ACS Nano; 2023 Nov; 17(21):22146. PubMed ID: 37909835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
